MorphoSys AG (ETR:MOR) has been given an average rating of “Buy” by the nine research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is €79.63 ($98.30).
Several equities analysts have recently issued reports on MOR shares. Deutsche Bank set a €90.00 ($111.11) price objective on MorphoSys and gave the stock a “buy” rating in a research report on Wednesday, November 8th. JPMorgan Chase & Co. restated a “buy” rating and issued a target price on shares of MorphoSys in a research report on Thursday, November 2nd. Berenberg Bank set a €85.00 ($104.94) target price on MorphoSys and gave the stock a “buy” rating in a research report on Thursday, December 7th. Goldman Sachs Group set a €72.00 ($88.89) target price on MorphoSys and gave the stock a “neutral” rating in a research report on Wednesday, November 8th. Finally, Independent Research set a €93.00 ($114.81) target price on MorphoSys and gave the stock a “buy” rating in a research report on Friday, December 1st.
MorphoSys (MOR) opened at €77.35 ($95.49) on Friday. The stock has a market capitalization of $2,280.00 and a P/E ratio of -26.22. MorphoSys has a 52-week low of €47.10 ($58.15) and a 52-week high of €87.05 ($107.47).
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.